Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 5, 2023

One case of comorbidity benefit of secukinumab for severe plaque psoriasis

Download as PDF

DOI: 10.23977/medsc.2023.040506 | Downloads: 18 | Views: 433

Author(s)

Fangfang Dong 1, Hui Wang 1, Chan Zhao 2

Affiliation(s)

1 First Clinical School of Medicine, Shaanxi University of Chinese Medicine, Xianyang, 712046, China
2 Department of Dermatology, Baoji Hospital of Traditional Chinese Medicine, Baoji, 721001, China

Corresponding Author

Chan Zhao

ABSTRACT

The patient was a 66-year-old male with recurrent erythematous and scaly plaques all over the body for more than 16 years. Generalized erythema on the head, trunk, and extremities, with some plaques fusing to form a map, covered with oyster shell-like hypertrophic white scales, film phenomenon (+), punctate hemorrhage (+), localized skin visible as scabs, scratches, and mossy changes, no pustules or joint swelling or deformity. Skin condition: PASI score: 56; BSA: 70%; DLQI: 17. Diagnosis: severe plaque psoriasis Metabolic syndrome. After administration of traditional treatments such as avitamin A, carbotriol ointment and glucocorticoids, which were ineffective, the skin lesions returned to normal and the psoriasis co-morbidities improved without adverse effects after treatment with stauchyuzumab.

KEYWORDS

Secukinumab, plaque psoriasis, IL-17A, psoriasis co-morbidities

CITE THIS PAPER

Fangfang Dong, Hui Wang, Chan Zhao, One case of comorbidity benefit of secukinumab for severe plaque psoriasis. MEDS Clinical Medicine (2023) Vol. 4: 37-42. DOI: http://dx.doi.org/10.23977/medsc.2023.040506.

REFERENCES

[1] Bens G, Maccari F, Estève E. Psoriasis: une maladie systémique [Psoriasis: a systemic disease]. Presse Med. 2012 Apr; 41(4):338-48. French. 
[2] Tashiro T, Sawada Y. Psoriasis and Systemic Inflammatory Disorders. Int J Mol Sci. 2022 Apr 18; 23(8):4457. 
[3] Psoriasis Professional Committee of the Chinese Medical Association, Dermatology, and Venereology Branch. Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition). Chinese Journal of Dermatology, 2019, 52(10):667-710. 
[4] Chinese Medical Association, Division of Diabetes. Chinese Guidelines for preventing and treating type 2 diabetes mellitus (2020 edition). Chinese Journal of Diabetes, 2021, 13(04):315-409. 
[5] Chinese Society of Dermatology and Venereology, Chinese Physicians Association, Chinese Society of Integrative Medicine, Chinese Society of Dermatology and Venereology. Guidelines for the treatment of psoriasis with biologic agents in China (2021). Chinese Journal of Dermatology, 2021, 54(12):1033-1047. 
[6] Zhang J C, Xing X H. Dermatologic venereology. 1 edition. Beijing: People's Health Publishing House, 2015: 204-207. 
[7] Lebwohl M. Psoriasis. Lancet. 2003 Apr 5; 361(9364):1197-204. 
[8] Ly K, Smith MP, Thibodeaux Q, et al. Anti-IL-17 in psoriasis. Expert Rev Clin Immunol. 2019 Nov; 15(11): 1185-1194. 
[9] von Stebut E, Reich K, Thaçi D, et al. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. J Invest Dermatol. 2019 May; 139(5): 1054-1062. 
[10] Gerdes S, Pinter A, Papavassilis C, et al. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol. 2020 Mar; 34(3):533-541. 

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4716
Visits: 205499

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.